Aayushi Mahajan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9079950/publications.pdf

Version: 2024-02-01

27 papers	894 citations	1163117 8 h-index	1281871 11 g-index
32 all docs	32 docs citations	32 times ranked	1762 citing authors

#	Article	IF	Citations
1	ETMM-04. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA MODEL SYSTEMS. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	0
2	ETMM-05. LACTIC ACID FACILITATES GLIOBLASTOMA GROWTH THROUGH MODULATION OF THE EPIGENOME. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	0
3	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. Clinical Cancer Research, 2021, 27, 5669-5680.	7.0	4
4	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nature Communications, 2021, 12, 5203.	12.8	38
5	TAMI-70. METABOLIC VULNERABILITY TO GPX4 INHIBITION AND FERROPTOSIS OF QUIESCENT ASTROCYTE-LIKE GLIOMA CELL POPULATIONS. Neuro-Oncology, 2021, 23, vi212-vi213.	1.2	0
6	Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology. Frontiers in Cell and Developmental Biology, 2021, 9, 766773.	3.7	4
7	TAMI-57. INDUCTION OF FERROPTOSIS PROMOTES IMMUNOGENIC CELL DEATH AND ACTIVATION OF THE IMMUNE MICROENVIRONMENT IN GLIOMA. Neuro-Oncology, 2021, 23, vi210-vi210.	1.2	2
8	MET Inhibition Elicits PGC1Î±-Dependent Metabolic Reprogramming in Glioblastoma. Cancer Research, 2020, 80, 30-43.	0.9	35
9	CD8+ T-cellâ€“Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clinical Cancer Research, 2020, 26, 4390-4401.	7.0	36
10	Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene, 2020, 39, 5068-5081.	5.9	21
11	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. Journal of Clinical Investigation, 2020, 130, 3699-3716.	8.2	104
12	Novel Pineal Germinoma Model Demonstrates Sensitivity to MTOR Inhibition. , 2020, 81, .		0
13	CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii47-ii48.	1.2	0
14	TAMI-33. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii220-ii220.	1.2	0
15	EPCO-16. LACTIC ACID IS AN EPIGENETIC METABOLITE THAT DRIVES GLIOBLASTOMA SURVIVAL AND GROWTH. Neuro-Oncology, 2020, 22, ii72-ii72.	1.2	0
16	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 2019, 25, 462-469.	30.7	569
17	IMMU-42. CD8+ T-CELLS MEDIATE IMMUNOEDITING, AND INFLUENCE GENOTYPE, TUMOR ONCOGENIC PATHWAYS AND MICROENVIRONMENT DURING PROGRESSION OF MURINE GLIOMAS. Neuro-Oncology, 2019, 21, vi128-vi128.	1.2	0
18	Abstract B165: Investigating in vivo synergistic effect of checkpoint blockade and radiation therapy against chordomas in a humanized mouse model. , 2019, , .		1

#	Article	IF	Citations
19	TMOD-37. IN VIVO SYNERGISTIC EFFECT OF CHECKPOINT BLOCKADE AND RADIATION THERAPY AGAINST CHORDOMAS IN A HUMANIZED MOUSE MODEL. Neuro-Oncology, 2018, 20, vi276-vi276.	1.2	1
20	GENE-17. TOP2B REGULATES CDK4 SPLICE VARIANTS IN GLIOMAS. Neuro-Oncology, 2018, 20, vi106-vi106.	1.2	0
21	DDIS-13. UNDERSTANDING GLIOBLASTOMA SUSCEPTIBILITY TO TOP2-TARGETING DRUGS FOR PERSONALIZED THERAPY. Neuro-Oncology, 2018, 20, vi71-vi72.	1.2	0
22	144 In Vivo Synergistic Effect of Checkpoint Blockade and Radiation Therapy Against Chordomas in a Humanized Mouse Model. Neurosurgery, 2018, 65, 95-96.	1.1	0
23	Friday, September 28, 2018 10:30 AMâ€“12:00 PM abstracts: innovation, surface technology and biomechanics. Spine Journal, 2018, 18, S90.	1.3	0
24	Abstract 5103: Notch is a master regulator of mesenchymal transformation and therapeutic resistance in glioma. , 2018, , .		0
25	Integrin signaling potentiates transforming growth factor-beta 1 (TGF-Î²1) dependent down-regulation of E-Cadherin expression â€“ Important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma. Experimental Cell Research, 2017, 355, 57-66.	2.6	44
26	GENE-08. PHARMACOLOGIC MODULATION OF MYC AND PDGFRA BY TARGETING TOPOISOMERASE II ON GLIOMAS. Neuro-Oncology, 2017, 19, vi94-vi94.	1.2	0
27	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. SSRN Electronic Journal, 0, , .	0.4	0